Clinical Reviews in Bone and Mineral Metabolism

, Volume 5, Issue 1, pp 27–38

Treatment of renal osteodystrophy

  • Anca Gal-Moscovici
  • Stuart M. Sprague
  • Edgar V. Lerma

DOI: 10.1007/BF02736669

Cite this article as:
Gal-Moscovici, A., Sprague, S.M. & Lerma, E.V. Clinic Rev Bone Miner Metab (2007) 5: 27. doi:10.1007/BF02736669


Chronic kidney disease (CKD) is accompanied by disturbances in calcium, phosphate, vitamin D, and parathyroid hormone (PTH) homeostasis known to play an important role in the pathophysiology of renal osteodystrophy. Increased cardiovascular morbidity and mortality rate among CKD patients, correlates with these disturbances in bone and mineral metabolism and underscores the nephrologist’s concern about the effectiveness of the present therapeutic approach. Treatment directed to normalize the calcium/phosphate, vitamin D and PTH abnormalities may adversely affect endothelial, vascular and bone cells activity. This article discusses the therapeutic approaches focuses for renal osteodystrophy.

Key Words

renal osteodystrophy phosphate binders vitamin D receptor agonist cinacalcet parathyroidectomy 

Copyright information

© Humana Press Inc 2007

Authors and Affiliations

  • Anca Gal-Moscovici
    • 1
    • 2
  • Stuart M. Sprague
    • 2
  • Edgar V. Lerma
    • 3
  1. 1.Hadassah Hospital Medical CenterHebrew UniversityEin Keren, JeruslaemIsrael
  2. 2.Division of Nephrology and Hypertension, Evanston Northwestern HealthcareNorthwestern University Feinberg School of MedicineEvanston
  3. 3.Section of NephrologyUniversity of Illinois at Chicago College of Medicine/Associates in NephrologyChicago
  4. 4.Evanston

Personalised recommendations